Company
Mesoblast
ASX:MSB / NASDAQ:MESO
First FDA-approved MSC product (Ryoncil).
At a glance
- Listing
- ASX:MSB / NASDAQ:MESO
- Category
- ASX listed
- Headquarters
- Melbourne
- Market cap
- ~A$2.6–2.8B
Thesis
Why it is in this universe
- Category
- ASX listed
- Market
- Australia
- Recent inflection
- Apr 2026 FDA IND clearance for Ryoncil in Duchenne MD; Ryoncil Y1 revenue ~US$100M.
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | ASX |
| Ticker | ASX:MSB / NASDAQ:MESO |
| Secondary listing | NASDAQ |
| Market cap | ~A$2.6–2.8B |
| Status | Listed and trading |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Melbourne
- Website
- No site on file
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
Apr 2026 FDA IND clearance for Ryoncil in Duchenne MD; Ryoncil Y1 revenue ~US$100M.
Common questions
- Why does variis track Mesoblast?
- First FDA-approved MSC product (Ryoncil).
- Is Mesoblast publicly listed?
- Yes. It trades as ASX:ASX:MSB / NASDAQ:MESO. Market capitalisation is in the ~A$2.6–2.8B range, recorded as a dated snapshot rather than a live quote.
- Where is Mesoblast based?
- Melbourne
- Is Mesoblast still trading?
- Mesoblast is recorded as actively trading.
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
No source is on file for this company yet. Treat everything above as unverified until one is.
Every entity profile on variis is sourced. Not investment advice.